A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab‑paclitaxel for resectable pancreatic cancer

Tajima,Hidehiro; Makino,Isamu; Gabata,Ryosuke; Okazaki,Mitsuyoshi; Ohbatake,Yoshinao; Shimbashi,Hiroyuki; Nakanuma,Shinich; Saitoh,Hiroto; Shimada,Mari; Yamaguchi,Takahisa; Okamoto,Koichi; Moriyama,Hideki; Kinoshita,Jun; Nakamura,Keishi; Miyashita,Tomoharu; Ninomiya,Itasu; Fushida,Sachio; Ikeda,Hiroko; Ohta,Tetsuo

doi:10.3892/mco.2020.2188

February-2021 Volume 14 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2021 Volume 14 Issue 2

Full Size Image

Article

A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab‑paclitaxel for resectable pancreatic cancer

Authors:
- Hidehiro Tajima
- Isamu Makino
- Ryosuke Gabata
- Mitsuyoshi Okazaki
- Yoshinao Ohbatake
- Hiroyuki Shimbashi
- Shinich Nakanuma
- Hiroto Saitoh
- Mari Shimada
- Takahisa Yamaguchi
- Koichi Okamoto
- Hideki Moriyama
- Jun Kinoshita
- Keishi Nakamura
- Tomoharu Miyashita
- Itasu Ninomiya
- Sachio Fushida
- Hiroko Ikeda
- Tetsuo Ohta
View Affiliations / Copyright

Affiliations: Department of Hepato‑Biliary‑Pancreatic Surgery, Division of Cancer Medicine, Graduate School of Medicine Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan, Department of Gastroenterological Surgery, Division of Cancer Medicine, Graduate School of Medicine Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan, Division of Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa 920‑8641, Japan
Article Number: 26
|
Published online on: December 14, 2020

https://doi.org/10.3892/mco.2020.2188
Expand metrics +

Abstract

Neoadjuvant chemotherapy (NAC) has become a standard treatment for borderline resectable pancreatic ductal adenocarcinoma (PDAC). The present study examined the maximum tolerated dose of NAC with gemcitabine plus nab‑paclitaxel (GnP) in patients with resectable PDAC. Between 2015 and 2019, 39 patients with resectable PDAC were enrolled in the present study. GnP was administered for two 28‑day cycles on days 1, 8 and 15. The planned doses for levels 1, 2 and 3 were 75, 100 and 125 mg/m², respectively, for nab‑paclitaxel and 600, 800 and 1,000 mg/m², respectively, for gemcitabine. Dose‑limiting toxicity (neutropenia, anemia, thrombocytopenia and/or liver injury) was observed in 44.4% of patients treated at dose level 1 (21 patients) and 60.0% of those treated at dose level 2 (18 patients). Therefore, the maximum tolerated dose was set as level 1. Six patients withdrew from protocol treatment because of non‑hematologic adverse events (skin rash, pancreatitis and biliary tract infection). Among the 31 patients with pathologically confirmed PDAC, partial response, stable disease and disease progression were recorded in 4 (12.9%), 24 (77.4%) and 3 (9.7%) patients, respectively. NAC significantly reduced tumor size according to computed tomography, and CA19‑9 levels and the ¹⁸F‑fluorodeoxyglucose maximum standardized uptake value were decreased in positron emission tomography. No postoperative complications attributable to NAC were recognized. Among the 27 patients with PDAC who underwent resection, the pathological treatment effect was judged as grades Ia, Ib and II in 21 (77.8%), 4 (14.8%) and 2 (7.4%) patients, respectively. R0 resection was performed in 24 out of 27 patients (88.9%). Adjuvant chemotherapy with oral S‑1 was administered to 21 out of 27 patients (77.8%). In conclusion, NAC with GnP was safe and feasible for resectable PDAC at dose level 1. In the future, verification of the long‑term results of the present study will be necessary, and a phase II clinical trial is anticipated.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.PubMed/NCBI View Article : Google Scholar
2	Cancer Research UK: Pancreatic Cancer Mortality Statistics. Available from: urihttp://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/mortality/simplehttp://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/mortality/.
3	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med. 364:1817–1825. 2011.PubMed/NCBI View Article : Google Scholar
4	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
5	Nagakawa T, Kurachi M, Konishi K and Miyazaki I: Translateral retroperitoneal approach in radical surgery for pancreatic carcinoma. Jpn J Surg. 12:229–233. 1982.PubMed/NCBI View Article : Google Scholar
6	Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, Ueno K and Miyazaki I: Result of extensive surgery for pancreatic carcinoma. Cancer. 77:640–645. 1996.PubMed/NCBI
7	Kitagawa H, Tajima H, Nakagawara H, Makino I, Miyashita T, Shoji M, Nakanuma S, Hayashi N, Takamura H, Ohta T and Ohtake H: En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma. Mol Clin Oncol. 2:369–374. 2014.PubMed/NCBI View Article : Google Scholar
8	Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. In: Cancer: Priciples and Practice of Oncology (6th edition). DeVita VT, Hellman S and Rosenberg SA (eds). Lippincott Williams and Wilkins, Philadelphia, PA, pp1126-1161, 2001.
9	Ottle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007.PubMed/NCBI View Article : Google Scholar
10	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomized, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.PubMed/NCBI View Article : Google Scholar
11	Klinlenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:776–784. 1999.PubMed/NCBI View Article : Google Scholar
12	Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA and Evans DB: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 15:928–937. 1997.PubMed/NCBI View Article : Google Scholar
13	Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, et al: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 225:621–636. 1997.PubMed/NCBI View Article : Google Scholar
14	Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H, et al: Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Therap Med. 3:787–792. 2012.PubMed/NCBI View Article : Google Scholar
15	Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et al: Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology Trial A021101. JAMA Surg. 151(e161137)2016.PubMed/NCBI View Article : Google Scholar
16	Shubert CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, Smoot RL, Kendrick ML, Nagorney DM and Farnell MB: Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National cancer database. Surgery. 160:1080–1096. 2016.PubMed/NCBI View Article : Google Scholar
17	Nagakawa Y, Hosokawa Y, Nakayama H, Sahara Y, Takishita C, Nakajima T, Hijikata Y, Kasuya K, Katsumata K, Tokuuye K and Tsuchida A: A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol. 79:951–957. 2017.PubMed/NCBI View Article : Google Scholar
18	Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, et al: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer-the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 18(1298)2018.PubMed/NCBI View Article : Google Scholar
19	Tajima H, Ohta T, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Kinoshita J, Makino I, Nakamura K, et al: Neoadjuvant chemotherapy with gemcitabine-based regimens improves prognosis of node positive resectable pancreatic head cancer. Mol Clinic Oncol. 11:157–166. 2019.PubMed/NCBI View Article : Google Scholar
20	Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, May 28, 2009.
21	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
22	Dino D, Demartines N and Clavian PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results lf a survey. Ann Surg. 240:205–213. 2004.PubMed/NCBI View Article : Google Scholar
23	Makino I, Kitagawa H, Ohta T, Nakagawara H, Tajima H, Ohnishi I, Takamura H, Tani T and Kayahara M: Nerve plexus invasion in pancreatic cancer: Spread patterns on histopathologic and embryological analysis. Pancreas. 37:358–365. 2008.PubMed/NCBI View Article : Google Scholar
24	Classification of Pancreatic Carcinoma (Fourth English Edition). Japan Pancreas Society, Kanehara & Co., Ltd., 2017.
25	Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, et al: The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 161:584–591. 2017.PubMed/NCBI View Article : Google Scholar
26	National Comprehensive Cancer Network: Practice guidelines in oncology for pancreatic adenocarcinoma version 1.2020, 2019.
27	Tajima H, Kitagawa H, Tsukada T, Nakanuma S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H, et al: A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Mol Clinic Oncol. 1:768–772. 2013.PubMed/NCBI View Article : Google Scholar
28	Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, et al: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 49:190–194. 2019.PubMed/NCBI View Article : Google Scholar
29	Miyasaka Y, Ohtsuka T, Kimura R, Matsuda R, Mori Y, Nakata K, Kakihara D, Fujimori N, Ohno T, Oda Y and Nakamura M: Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol. 26:1528–1534. 2019.PubMed/NCBI View Article : Google Scholar
30	Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, et al: Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 270:400–413. 2019.PubMed/NCBI View Article : Google Scholar
31	Okada K, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Hayami S and Yamaue H: Phase I study of Nab-Paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 37:853–858. 2017.PubMed/NCBI View Article : Google Scholar
32	Valle S, Martin-Hijano L, Alcalá S, Alonso-Nocelo M and Sainz B Jr: The ever-evolving concept of the cancer stem cell in pancreatic cancer. Cancers (Basel). 10(33)2018.PubMed/NCBI View Article : Google Scholar
33	Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010.PubMed/NCBI View Article : Google Scholar
34	Zhou J, Zhong DW, Wang QW, Miao XY and Xu XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol. 16:3330–3334. 2010.PubMed/NCBI View Article : Google Scholar
35	Choi HS, Savard CE, Choi JW, Kuver R and Lee SP: Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts. J Surg Res. 141:183–191. 2007.PubMed/NCBI View Article : Google Scholar
36	Hirose A, Tajima H, Ohta T, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H, et al: Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. Oncol Lett. 6:915–920. 2013.PubMed/NCBI View Article : Google Scholar
37	Miyashita T, Tajima H, Makino I, Okazaki M, Yamaguchi T, Ohbatake Y, Nakanuma S, Hayashi H, Takamura H, Ninomiya I, et al: Neoadjuvant chemotherapy with gemcitabine plus Nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma. Anticancer Res. 38:337–343. 2018.PubMed/NCBI View Article : Google Scholar
38	Chan KKW, Guo H, Cheng S, Beca JM, Redmond-Misner R, Isaranuwatchai W, Qiao L, Earle C, Berry SR, Biagi JJ, et al: Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Cancer Med. 9:160–169. 2020.PubMed/NCBI View Article : Google Scholar
39	Dhir M, Zenati MS, Hamad A, Singhi AD, Bahary N, Hogg ME, Zeh HJ III and Zureikat AH: FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol. 25:1896–1903. 2018.PubMed/NCBI View Article : Google Scholar
40	Polistina F, Di Natale G, Bonciarelli G, Ambfosino G and Frego M: Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol. 20:9374–9383. 2014.PubMed/NCBI View Article : Google Scholar
41	Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: A systemic review and meta-analysis of response and resection percentages. PLoS Med. 7(e1000267)2010.PubMed/NCBI View Article : Google Scholar
42	Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, et al: Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 111:152–165. 2017.PubMed/NCBI View Article : Google Scholar
43	Nakayama A, Ninomiya I, Harada S, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, et al: Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. Int J Oncol. 49:1890–1898. 2016.PubMed/NCBI View Article : Google Scholar
44	Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 28:4450–4456. 2010.PubMed/NCBI View Article : Google Scholar
45	Mochizuki K, Gabata T, Kozaka K, Hattori Y, Zen Y, Kitagawa H, Kayahara M, Ohta T and Matsui O: MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma: Correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol. 20:1757–1767. 2010.PubMed/NCBI View Article : Google Scholar